| Literature DB >> 33369136 |
Pierre Peterlin1,2, Joelle Gaschet2, Thierry Guillaume1,2, Alice Garnier1, Marion Eveillard2,3, Amandine Le Bourgeois1, Michel Cherel2,4, Camille Debord3, Yannick Le Bris2,3, Olivier Theisen3, Catherine Godon3, Béatrice Mahé1, Viviane Dubruille1, Soraya Wuilleme3, Cyrille Touzeau1, Thomas Gastinne1, Nicolas Blin1, Anne Lok1, Benoît Tessoulin1, Steven Le Gouill1,2, Philippe Moreau1,2, Marie-C Béné2,3, Patrice Chevallier1,2.
Abstract
The aim of this study was to assess the potential impact of the kinetics of serum levels of seven cytokines during induction in acute myeloid leukemia (AML) patients. Indeed, the role of cytokines, in the pathophysiology and response to therapy of AML patients, remains under investigation. Here, we report on the impact of peripheral levels of two cytokines, the Fms-like tyrosine kinase 3 ligand (FL) and interleukin-6 (IL-6), evaluated during first-line intensive induction. A new risk stratification can be proposed, which supersedes the ELN 2017 classification to predict survivals in AML patients by examining the kinetic profile of these cytokines during the induction phase. It segregates three groups of, respectively, high-risk, characterized by a stagnation of low FL levels, intermediate risk, with dynamic increasing FL levels and high IL-6 at day 22, and favorable risk with increasing FL levels but low IL-6 at day 22.Entities:
Keywords: FLT3 ligand; IL-6; acute myeloid leukemia; prognostic biomarker
Mesh：
Substances：
Year: 2020 PMID： 33369136 PMCID： PMC7877358 DOI： 10.1002/cam4.3648
Source DB: PubMed Journal: Cancer Med ISSN： 2045-7634 Impact factor: 4.452